Compare Stocks: VALN, VERA, NKTR, and PGEN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NKTR Nektar Therapeutics	$76.19 +2.7%	$71.98	$33.40 ▼ $109.00	$2.61B	1.14	997,393 shs	484,482 shs
PGEN Precigen	$6.98 -1.8%	$6.22	$2.99 ▼ $7.72	$2.49B	1.02	4.62 million shs	1.26 million shs
VALN Valneva	$6.96 +1.0%	$5.72	$4.75 ▼ $12.23	$660.43M	1.67	66,999 shs	15,386 shs
VERA Vera Therapeutics	$35.16 -2.0%	$35.72	$22.72 ▼ $56.05	$2.54B	0.96	1.50 million shs	442,641 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NKTR Nektar Therapeutics	0.00%	+3.94%	-2.99%	+31.94%	+84.64%
PGEN Precigen	0.00%	+2.45%	-1.80%	+91.37%	+62.84%
VALN Valneva	0.00%	+9.37%	+30.00%	+29.76%	-20.35%
VERA Vera Therapeutics	0.00%	+5.31%	+9.12%	+12.83%	+48.37%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NKTR Nektar Therapeutics	$76.19 +2.7%	$71.98	$33.40 ▼ $109.00	$2.61B	1.14	997,393 shs	484,482 shs
PGEN Precigen	$6.98 -1.8%	$6.22	$2.99 ▼ $7.72	$2.49B	1.02	4.62 million shs	1.26 million shs
VALN Valneva	$6.96 +1.0%	$5.72	$4.75 ▼ $12.23	$660.43M	1.67	66,999 shs	15,386 shs
VERA Vera Therapeutics	$35.16 -2.0%	$35.72	$22.72 ▼ $56.05	$2.54B	0.96	1.50 million shs	442,641 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NKTR Nektar Therapeutics	0.00%	+3.94%	-2.99%	+31.94%	+84.64%
PGEN Precigen	0.00%	+2.45%	-1.80%	+91.37%	+62.84%
VALN Valneva	0.00%	+9.37%	+30.00%	+29.76%	-20.35%
VERA Vera Therapeutics	0.00%	+5.31%	+9.12%	+12.83%	+48.37%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NKTR Nektar Therapeutics	2.77	Moderate Buy	$141.50	85.73% Upside
PGEN Precigen	2.80	Moderate Buy	$14.50	107.89% Upside
VALN Valneva	1.67	Reduce	$9.30	33.62% Upside
VERA Vera Therapeutics	2.86	Moderate Buy	$80.15	127.94% Upside

Current Analyst Ratings Breakdown

Latest VALN, VERA, NKTR, and PGEN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/8/2026	VERA Vera Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$76.00 ➝ $83.00
8/28/2026	NKTR Nektar Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/24/2026	NKTR Nektar Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	NKTR Nektar Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$65.00
8/17/2026	VERA Vera Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$34.00
8/12/2026	VERA Vera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$125.00 ➝ $90.00
8/11/2026	VERA Vera Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$84.00
8/11/2026	VALN Valneva	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
8/11/2026	VALN Valneva	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
8/11/2026	VERA Vera Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$43.00 ➝ $34.00
8/5/2026	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$14.00 ➝ $18.00

(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NKTR Nektar Therapeutics	$55.23M	47.09	N/A	N/A	$4.41 per share	17.28
PGEN Precigen	$9.68M	256.89	N/A	N/A	$0.06 per share	116.25
VALN Valneva	$197.56M	3.34	N/A	N/A	$1.39 per share	5.01
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	$8.48 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NKTR Nektar Therapeutics	-$164.08M	-$6.70	N/A	N/A	N/A	-287.84%	-37.87%	-25.67%	11/5/2026 (Estimated)
PGEN Precigen	-$250.64M	-$1.04	N/A	8.11	N/A	-183.98%	423.75%	84.39%	11/12/2026 (Estimated)
VALN Valneva	-$130.33M	-$2.11	N/A	15.82	N/A	-110.33%	-153.20%	-39.50%	11/19/2026 (Estimated)
VERA Vera Therapeutics	-$299.61M	-$5.86	N/A	N/A	N/A	N/A	-84.13%	-66.79%	11/4/2026 (Estimated)

Latest VALN, VERA, NKTR, and PGEN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	VALN Valneva	-$0.1886	-$0.40	-$0.2114	-$0.38	$44.17 million	$39.37 million
8/13/2026	Q2 2026	NKTR Nektar Therapeutics	-$1.97	-$1.23	+$0.74	-$1.23	$10.43 million	$10.13 million
8/10/2026	Q2 2026	VERA Vera Therapeutics	-$1.58	-$1.52	+$0.06	-$1.52	$1.28 million	N/A
8/4/2026	Q2 2026	PGEN Precigen	-$0.0121	$0.05	+$0.0621	$0.05	$27.98 million	$54.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A
VALN Valneva	N/A	N/A	N/A	N/A	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NKTR Nektar Therapeutics	N/A	10.42	10.42
PGEN Precigen	2.15	4.58	3.89
VALN Valneva	2.04	2.16	1.69
VERA Vera Therapeutics	0.18	10.92	10.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NKTR Nektar Therapeutics	75.88%
PGEN Precigen	33.51%
VALN Valneva	11.39%
VERA Vera Therapeutics	99.21%

Insider Ownership

Company	Insider Ownership
NKTR Nektar Therapeutics	2.50%
PGEN Precigen	41.40%
VALN Valneva	14.91%
VERA Vera Therapeutics	15.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NKTR Nektar Therapeutics	220	34.14 million	33.29 million	Optionable
PGEN Precigen	190	356.51 million	208.92 million	Optionable
VALN Valneva	700	94.89 million	80.74 million	Not Optionable
VERA Vera Therapeutics	40	72.06 million	60.61 million	Optionable

VALN, VERA, NKTR, and PGEN Headlines

Recent News About These Companies

JPMorgan Chase & Co. Issues Positive Forecast for Vera Therapeutics (NASDAQ:VERA) Stock Price

1 hour ago | marketbeat.com

Readystate Asset Management LP Takes Position in Vera Therapeutics, Inc. $VERA

September 7 at 5:51 AM | marketbeat.com

Insider Selling: Vera Therapeutics (NASDAQ:VERA) CEO Sells $649,720.00 in Stock

September 7 at 4:23 AM | americanbankingnews.com

Vera Therapeutics (NASDAQ:VERA) CEO Sells $649,720.00 in Stock

September 4, 2026 | marketbeat.com

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 4, 2026 | globenewswire.com

Braidwell LP Purchases 40,900 Shares of Vera Therapeutics, Inc. $VERA

September 3, 2026 | marketbeat.com

Vera Therapeutics to Participate at Upcoming Investor Conferences

September 1, 2026 | globenewswire.com

AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual ...

August 31, 2026 | joplinglobe.comJ

Vera Therapeutics (NASDAQ:VERA) Trading Down 5.2% - What's Next?

August 27, 2026 | marketbeat.com

Vera Therapeutics, Inc. $VERA Stock Position Raised by Odyssean LLC

August 26, 2026 | marketbeat.com

Vera Therapeutics Sees Unusually Large Options Volume (NASDAQ:VERA)

August 25, 2026 | marketbeat.com

Vera Therapeutics, Inc. (VERA) Stock Price, News, Quote & History - Yahoo Finance

August 25, 2026 | finance.yahoo.com

Vera Therapeutics (NASDAQ:VERA) Stock Price Up 6.2% - Here's What Happened

August 24, 2026 | marketbeat.com

Vera Therapeutics (NASDAQ:VERA): What Could Drive the Next Move?

August 19, 2026 | kalkinemedia.comK

J.P. Morgan Sticks to Their Buy Rating for Vera Therapeutics (VERA)

August 19, 2026 | theglobeandmail.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Rating of "Moderate Buy" from Analysts

August 19, 2026 | marketbeat.com

Bank of America Corp DE Has $23.72 Million Stake in Vera Therapeutics, Inc. $VERA

August 18, 2026 | marketbeat.com

Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buy

August 17, 2026 | seekingalpha.com

Wedbush Reiterates Neutral Rating for Vera Therapeutics (NASDAQ:VERA)

August 17, 2026 | marketbeat.com

Vera Therapeutics (NASDAQ:VERA) Shares Gap Up - Here's Why

August 14, 2026 | marketbeat.com

HC Wainwright Has Positive Estimate for VERA Q3 Earnings

August 14, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VALN, VERA, NKTR, and PGEN Company Descriptions

Nektar Therapeutics NASDAQ:NKTR

$76.19 +2.00 (+2.69%)

As of 01:50 PM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Precigen NASDAQ:PGEN

$6.98 -0.13 (-1.76%)

As of 01:49 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Valneva NASDAQ:VALN

$6.96 +0.07 (+1.02%)

As of 01:46 PM Eastern

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

Vera Therapeutics NASDAQ:VERA

$35.16 -0.73 (-2.02%)

As of 01:50 PM Eastern

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VALN, VERA, NKTR, and PGEN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VALN, VERA, NKTR, and PGEN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VALN, VERA, NKTR, and PGEN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VALN, VERA, NKTR, and PGEN Company Descriptions

Nektar Therapeutics NASDAQ:NKTR

Precigen NASDAQ:PGEN

Valneva NASDAQ:VALN

Vera Therapeutics NASDAQ:VERA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VALN, VERA, NKTR, and PGEN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VALN, VERA, NKTR, and PGEN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VALN, VERA, NKTR, and PGEN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VALN, VERA, NKTR, and PGEN Company Descriptions

Nektar Therapeutics NASDAQ:NKTR

Precigen NASDAQ:PGEN

Valneva NASDAQ:VALN

Vera Therapeutics NASDAQ:VERA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools